<qa>  To estimate recurrence free survival of a dose-dense regimen ofII. To estimate recurrence free survival of a dose-dense regimen of cyclophosphamide and paclitaxel with trastuzumab in subjects with newly diagnosed stage I-II HER2neu positive breast cancer. 